ABBV AbbVie Inc: רווח למניה בשנים עשר החודשים האחרונים

AbbVie Inc (ABBV) - לוגו תאגידי

The YoY EPS change on a rolling 12-month basis demonstrates the resilience of the biopharmaceutical behemoth AbbVie Inc. (ABBV), which relies on patent-protected oncology and immunology developments. Business efficiency is based on clinical trial results and government price regulation, while 338.50 expresses the metric's value today. The decline in Humira revenues due to biosimilars is partially offset by new products, mitigating regulatory risks.

ABBV: רווח נקי למניה (EPS TTM) AbbVie 11.02.2024 - 17.11.2026

AbbVie Corp. - פילוחים אנליטיים ומדדי מפתח (ABBV)

- מחיר ותחזית קונצנזוס למחירים:
- נתוני שווי מניות החברה:
הערכת שווי פונדמנטלית של החברה:ABBV - AbbVie
מוצרים מוגמרים של Abbvie

This indicator captures the percentage change in earnings per share within a rolling annual window. By analyzing current EPS YoY TTM trends, investors can track the business scaling speed between official reports. The metric is calculated as the difference between the current and previous twelve-month EPS values. For AbbVie Inc. (ABBV), this growth confirms the effectiveness of its patent strategy and its ability to maintain pricing power against generics.